Cerebrolysin is a porcine brain-derived peptide mixture used for neuroprotection and cognitive support. People typically run it at 500 mcg/day, though dosing schedules are often unspecified. The off-label evidence base is thinner than commonly suggested, with most exploratory indications lacking posted results, and community discussion notes variable individual response and recurring injection-site reactions.

Research Evidence
Evidence shape
Clinical evidence for Cerebrolysin sits at a moderate tier, with the strongest data coming from Phase 3 trials that showed modest improvements in Alzheimer disease (≈‑0.6 points) and acute cerebral stroke treated within 12 hours (≈+1.0 units). The research portfolio covers 28 distinct neurological indications, backed by 12 sponsors and three blinded studies that have posted results, while the remaining trials are largely exploratory, single‑trial or still recruiting. The lack of published outcomes for most indications signals that robust evidence is limited to the few reported endpoints.
Anecdotal efficacy
Side effects
Clinical research side effects
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Cerebrolysin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
5 completed trials identified; trial dosing not reliably extracted from registry data.
No structured protocol details captured for this tier yet.
Reported doses span 500 µg, most commonly 500 µg; most posters do not state a schedule.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
Forum threadLive community discussion for Cerebrolysin, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.